Firstly my guess is that Biogen has people leading the charge who are vastly more experienced at dealing with the FDA than anyone  RVX has so are likely dealing with the FDA at a more senior level. Biogen also has deep pockets and probably responds very quickly and meaningfully to the FDA and could and would likely promise large follow on trials. From what we have seen, Resverlogix does not seem to have the management capabilities or finances to make quick promises for follow on trials or to really act on anything in a timely manner. Money and experience can get a lot done, with those two factors working never say never.